As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

Well, in this video, that's exactly what happened to me! Join me on a wild and crazy adventure as I chase down my Uber Eats ...

April 2025. More for You ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.

In a report released today, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target of ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

Given this risk, we thought we'd take a look at whether 10x Genomics (NASDAQ:TXG) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Detailed price information for Torex Gold Resources Inc (TXG-T) from The Globe and Mail including charting and trades.